Ed Albini | Sutro Biopharma, Inc.

Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares South San Francisco, Calif., May 14, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery,...

Sutro Biopharma Announces Pricing of $85.3 Million Public Offering

News, Press Releases

Sutro Biopharma Announces Pricing of $85.3 Million Public Offering South San Francisco, Calif., May 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated...

Dr. Wendel Naumann of The Levine Cancer Institute, Virtual Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020

News, Presentations

Dr. Wendel Naumann of The Levine Cancer Institute, Virtual Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 Dr. Wendel Naumann of The Levine Cancer Institute,...

Sutro Biopharma to Host Analyst and Investor Conference Call April 27, 2020 – PowerPoint Presentation

Events, News, Presentations

Sutro Biopharma to Host Analyst and Investor Conference Call April 27, 2020 – PowerPoint Presentation Download Presentation CLICK HERE Download...

Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer –...

« Older Entries